PYXS Stock Forecast: Pyxis Oncology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.80
+7.14% on the day

The median 12-month analyst price target for Pyxis Oncology, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 74 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$216.5M
Ticker Nerd rank
74/ 100
Median analyst target
$7.00
Analysts covering
9
Revenue$0.0−100.0% y/y
Operating income−$26.0M
Net income−$25.3M
Free cash flow−$18.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.9%
1M
−2.2%
YTD
+56.5%
1Y
−60.3%
From 52W high
−66.3%
From 52W low
+69.8%
$1.06
$5.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pyxis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
74/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
88
Accruals
85
Revisions
69
Value
68
Issuance
48
Volatility
41
Momentum
38
Quality
32

Growth (88): Sales and profits are climbing, and climbing faster than before.

Quality (32): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PYXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PYXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26PYXSHigh $19.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$5.00
Low
$7.00
Median
$19.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026RBC CapitalMaintainsOutperform$6.00 → $7.00
6 Nov 2026WedbushMaintainsOutperform$8.00 → $7.00
10 Sept 2026HC Wainwright & Co.MaintainsBuy$7.00 → $8.00
10 Sept 2026WedbushMaintainsOutperform$6.00 → $8.00
9 Sept 2026RBC CapitalMaintainsOutperform—
9 Sept 2026Wells FargoMaintainsOverweight$12 → $19
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$7.00
3 Aug 2026Wells FargoInitiatesOverweight$12
2 July 2026Leerink PartnersMaintainsOutperform$9.00 → $7.00
5 May 2026WedbushInitiatesOutperform—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Mar 2026StifelMaintainsBuy—
19 Dec 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2025RBC CapitalMaintainsOutperform—
24 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025GuggenheimMaintainsBuy—
4 Sept 2025GuggenheimInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PYXS.

Market Radar

This page is one stock. Monday covers all of them.

PYXS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PYXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pyxis Oncology, Inc. returned −60.3% against +6.9% for the S&P 500, dividends included.

PYXS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PYXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PYXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
19.6×

Cheaper than 8% of US stocks

Price / book
3.7×

Cheaper than 26% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−157.5%

Higher than 9% of US stocks

Return on assets
−59.9%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pyxis Oncology, Inc. has a market value of $216.5M and an enterprise value of $178.3M.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$88.7M, a −803.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$67.9M.

  • Shares outstanding: 63.4M.

  • Pyxis Oncology, Inc. employs 56 people — $197K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

PYXS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PYXSPyxis Oncology, Inc.$216.5M74
KROSKeros Therapeutics, Inc.$218.5M83
IMRXImmuneering Corp.$218.9M48
ARCTArcturus Therapeutics Holdings, Inc.$211.7M74
RCKTRocket Pharmaceuticals, Inc.$211.0M36
ENTAEnanta Pharmaceuticals, Inc.$221.9M79
IPSCCentury Therapeutics, Inc.$209.3M44

Take a look at PYXS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pyxis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PYXS

What is the PYXS stock price forecast for 2026-2027?

The median 12-month analyst price target for Pyxis Oncology, Inc. is $7, with estimates ranging from $5 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PYXS stock a buy right now?

Of the 9 analysts covering Pyxis Oncology, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pyxis Oncology, Inc. 74 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PYXS?

As at 21 Nov 2026, Pyxis Oncology, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).

Will PYXS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $7, and Ticker Nerd's factor model ranks Pyxis Oncology, Inc. 74 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PYXS stock forecast for 2030?

No analyst covering Pyxis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $19 over the next 12 months.

How has PYXS stock performed over the past year?

Pyxis Oncology, Inc. returned -60.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pyxis Oncology, Inc. do?

Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer.

Company

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.

CEO Mr. Thomas Civik · 56 employees · United States · https://www.pyxisoncology.com